Clofarabine and CY do not yield reliable engraftment of hematopoietic stem cells

Karch, Jon; Zhu, Jian; Ehmann, W. Christopher; Claxton, David F.

doi:10.1038/bmt.2011.224

Cited by 2 publications

(1 citation statement)

References 7 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Among the various CLO combined conditioning regimens, the use of BU seemed most effective and safe according to the available literature. [5][6][7]16,17 Magenau et al 5 reported a phase 1/2 study of CLO/BU conditioning for 46 patients with various hematologic malignancies. Notably, although the study included relatively older patients with a history of previous BMT, the regimen was tolerable.…”

Section: Discussionmentioning

confidence: 98%

Haploidentical Bone Marrow Transplantation With Clofarabine and Busulfan Conditioning for a Child With Multiple Recurrent Acute Lymphoblastic Leukemia

Aoki

Miyawaki

Imai

et al. 2016

Journal of Pediatric Hematology/Oncology

View full text Add to dashboard Cite

Outcome of children with acute lymphoblastic leukemia (ALL) has improved over the years, but not for those with multiple recurrences because of high therapy resistance and heavily pretreated history that potentially cause physical damages. We describe the case of an 11-year-old boy with a third relapse of ALL and a history of 2 allogeneic bone marrow transplantations. He was successfully treated with clofarabine combination chemotherapy and achieved a fourth remission at 16 months following haploidentical bone marrow transplantation with conditioning regimen of clofarabine and busulfan. Clofarabine/busulfan conditioning might be a preferable option for children with multiple recurrent ALL, and warrants further investigation.

show abstract

Section: Discussionmentioning

confidence: 98%

Haploidentical Bone Marrow Transplantation With Clofarabine and Busulfan Conditioning for a Child With Multiple Recurrent Acute Lymphoblastic Leukemia

Aoki

Miyawaki

Imai

et al. 2016

Journal of Pediatric Hematology/Oncology

View full text Add to dashboard Cite

show abstract

Clofarabine followed by haploidentical stem cell transplant using fludarabine, busulfan, and total-body irradiation with post-transplant cyclophosphamide in non-remission AML

et al. 2018

View full text Add to dashboard Cite

Approximately 30-40% of patients with acute myeloid leukemia (AML) experience induction failures. In these patients who do not achieve remission with two cycles of standard induction therapies, the probability of achieving remission with subsequent inductions is very limited. Hematopoietic stem cell transplantation (HSCT) is the only curative option for these patients, but high relapse rate and transplant-related mortality often preclude them to proceed to transplant. Thus, AML not in remission at time of HSCT remains a huge unmet need in current HSCT practice, particularly if the patient does not have an HLA-matched donor identified by the time of two induction failures. We used clofarabine cytoreduction immediately followed by fludarabine (Flu) and busulfan (Bu) × 3 with total-body irradiation (TBI) conditioning (Flu/Bu3/TBI) for haploidentical peripheral blood stem cell transplant with post-transplant cyclophosphamide for two cases of refractory AML with a very high tumor burden at transplant and achieved complete remission by day + 30 in both cases.

show abstract

Clofarabine and CY do not yield reliable engraftment of hematopoietic stem cells

Cited by 2 publications

References 7 publications

Haploidentical Bone Marrow Transplantation With Clofarabine and Busulfan Conditioning for a Child With Multiple Recurrent Acute Lymphoblastic Leukemia

Haploidentical Bone Marrow Transplantation With Clofarabine and Busulfan Conditioning for a Child With Multiple Recurrent Acute Lymphoblastic Leukemia

Clofarabine followed by haploidentical stem cell transplant using fludarabine, busulfan, and total-body irradiation with post-transplant cyclophosphamide in non-remission AML

Contact Info

Product

Resources

About